PSTV

Plus Therapeutics Inc.

Price

return (12m)

p/e

0.00

p/bv

0.00

DIVIDEND YIELD

0.00%

PSTV price

Plus Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment PSTV

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals PSTV

Valuation

P/E

0.00

Sector -4.26

Industry -4.26

P/BV

0.00

Sector 2.11

Industry 2.11

P/Revenue (PSR)

Sector 2.08

Industry 2.08

EV/EBITDA

2.21

Sector -546.19

Industry -546.19

EV/EBIT

2.18

Sector -37.31

Industry -37.31

P/EBITDA

Sector -50.76

Industry -50.76

P/EBIT

Sector -39.62

Industry -39.62

P/Total Assets

Sector 1.25

Industry 1.25

P/Net Current Assets

0.00

Sector -5.47

Industry -5.47

P/Working Capital

0.00

Sector -1.10

Industry -1.10

EPS

-1.70

Sector -1.94

Industry -1.94

BVPS

1.71

Sector 1.89

Industry 1.89

Efficiency

Gross Margin

0.00%

Sector 38.90%

Industry 38.90%

EBITDA Margin

Sector -13,872.56%

Industry -13,872.56%

EBIT Margin

Sector -4,253,834.43%

Industry -4,253,834.43%

Operating Margin

0.00%

Sector -36.74%

Industry -36.74%

Net Profit Margins

0.00%

Sector -37.51%

Industry -37.51%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-99.75%

Sector -61.50%

Industry -61.50%

ROA

-59.89%

Sector -63.85%

Industry -63.85%

ROIC

-488.61%

Sector -498.30%

Industry -498.30%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

2.27

Sector 2.89

Industry 2.89

Net Debt / EBITDA

2.21

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

2.18

Sector -10.24

Industry -10.24

Net Debt / Equity

-1.26

Sector -0.60

Industry -0.60

Gross Debt / Equity

0.00

Sector -0.83

Industry -0.83

Equity/Assets

0.60

Sector 0.43

Industry 0.43

Liabilities/Assets

0.40

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

-2.30%

Sector -

Industry -

Fundamentals PSTV

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
PSTV Plus Therapeutics Inc.	$0.00	-100.00%	0.00%	0.00	0.00	-99.75%	0.00%
JNJ Johnson & Johnson	$266.50	55.29%	1.93%	31.09	7.70	24.76%	21.48%
PFE Pfizer Inc.	$27.87	21.03%	6.26%	35.86	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$256.91	27.42%	2.58%	74.16	-78.93	-106.44%	9.81%
NVO Novo Nordisk A/S	$45.62	-14.65%	3.95%	11.47	6.09	53.11%	35.32%
MRK Merck & Co. Inc.	$147.77	82.61%	2.24%	116.78	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$161.98	3.71%	1.93%	24.59	5.10	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$66.29	45.78%	3.73%	14.81	6.16	41.55%	18.85%
ZTS Zoetis Inc.	$76.84	-49.43%	2.67%	12.20	10.25	84.02%	27.77%
REGN Regeneron Pharmaceuticals Inc.	$792.43	37.47%	0.44%	19.71	2.69	13.65%	27.86%
AMGN Amgen Inc.	$432.42	55.55%	2.22%	27.25	20.39	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$105.00	43.48%	0.00%	30.73	88.55	288.14%	24.86%
MCK McKesson Corporation	$897.16	31.93%	0.38%	19.60	-26.88	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$542.40	39.41%	0.00%	31.57	6.87	21.76%	35.00%
CAH Cardinal Health Inc.	$235.19	59.60%	0.88%	35.20	-20.39	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$39.29	3.26%	0.00%	12.32	2.23	18.14%	18.89%
BIIB Biogen Inc.	$217.24	59.31%	0.00%	38.68	1.71	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

PSTV Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Plus Therapeutics

Plus Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

29 years

Founded: 1997

2000

Time since IPO - 26 years

12

Employees

Plus Therapeutics Inc. operates in the healthcare sector within the biotechnology industry, focusing on the development of targeted radiopharmaceutical therapies for cancer treatment.

Its main areas of activity include:

• Development of radiopharmaceutical therapies for solid tumors.
• Clinical research and early-stage clinical trials.
• Drug-delivery platforms using radioisotopes.
• Regulatory support and oncology-focused research partnerships.

The company is developing therapies aimed at central nervous system tumors and metastatic cancers, using controlled delivery systems to improve treatment precision and effectiveness.

Industry dynamics affecting the company include regulatory requirements for advanced therapies, high research and development costs, competition in radiopharmaceutical innovation and increasing demand for targeted cancer treatments.

Shares of Plus Therapeutics Inc. trade on the Nasdaq under the ticker PSTV.

History and Development

Plus Therapeutics was founded in 1996 with an initial focus on controlled drug-delivery technologies and targeted therapeutic solutions.

In its early years, the company concentrated on building research capabilities, establishing clinical partnerships and advancing experimental treatment platforms. Growth was driven by expansion into oncology-focused applications and the development of radiopharmaceutical therapies.

Over time, the company broadened its clinical pipeline and strengthened collaborations with medical centers and research institutions. A key milestone occurred in 2019 with a corporate rebranding and strategic shift toward radiopharmaceutical technologies.

In recent years, the company has operated in an environment shaped by advances in precision oncology, regulatory complexity and evolving biotechnology market conditions. It has focused on progressing clinical trials, refining its therapeutic platforms and expanding partnerships, supporting the development of targeted cancer treatments.

Additional Information

Plus Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $-, with shareholders equity totaling $11.96 million.

The company employs approximately 12 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Plus Therapeutics Inc. reported $- in revenue, generating net income of $-11.93 million.

Key financial metrics include a P/E ratio of 0.00, a price-to-book (P/B) ratio of 0.00, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker PSTV.

Market cap

Net worth

$11.96 million

$11,960,000.00

Assets

$19.92 million

$19,920,000.00

Total Shares Outstanding

7.00 million

7,000,000

Average Daily Trading Volume

$158.58 Thousand

$158,583.50

Sector

Health Care

Industry

Biotechnology

PSTV

PSTV revenue and profits

Financial Results PSTV

DRAG THE FRAME TO SEE MORE DATA

PSTV cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$897.16 31,33% (12M)

P/E

19.60

0.38%

ROE

-137.16%

P/BV

-26.88

CAH - Cardinal Health

$235.19 60,10% (12M)

P/E

35.20

0.88%

ROE

-57.93%

P/BV

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12M)

P/E

31.09

1.93%

ROE

24.76%

P/BV

7.70

ABBV - AbbVie

$256.91 26,00% (12M)

P/E

74.16

2.58%

ROE

-106.44%

P/BV

-78.93

MRK - Merck & Co.

$147.77 82,50% (12M)

P/E

116.78

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$161.98 3,46% (12M)

P/E

24.59

1.93%

ROE

20.74%

P/BV

5.10

PFE - Pfizer

$27.87 22,54% (12M)

P/E

35.86

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$897.16 31,33% (12 M)

P/L

19.60

0.38%

ROE

-137.16%

P/VP

-26.88

CAH - Cardinal Health

$235.19 60,10% (12 M)

P/L

35.20

0.88%

ROE

-57.93%

P/VP

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12 M)

P/L

31.09

1.93%

ROE

24.76%

P/VP

7.70

ABBV - AbbVie

$256.91 26,00% (12 M)

P/L

74.16

2.58%

ROE

-106.44%

P/VP

-78.93

MRK - Merck & Co.

$147.77 82,50% (12 M)

P/L

116.78

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$161.98 3,46% (12 M)

P/L

24.59

1.93%

ROE

20.74%

P/VP

5.10

PFE - Pfizer

$27.87 22,54% (12 M)

P/L

35.86

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Plus Therapeutics (PSTV) today?

A cotação de Plus Therapeutics (PSTV) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Plus Therapeutics (PSTV) iniciou o ano negociando na casa dos US$ 0.51 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Plus Therapeutics (PSTV) e dados de ações do Ibovespa e mercados internacionais.

Quando Plus Therapeutics (PSTV) paga dividendos?

Plus Therapeutics (PSTV) não distribuiu dividendos no último ano.

Is Plus Therapeutics (PSTV) a good investment?

Atualmente, Plus Therapeutics (PSTV) está cotada a US$ 0.00, com um P/L de 0.00, representando um desvio de -73% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Plus Therapeutics (PSTV) stock?

Investir em ações de Plus Therapeutics (PSTV) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Plus Therapeutics (PSTV) yield today?

A rentabilidade de Plus Therapeutics (PSTV) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Plus Therapeutics (PSTV) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

PSTV

Plus Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment PSTV

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING PSTV WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Plus Therapeutics

Plus Therapeutics Inc.

United States

29 years

2000

12

History and Development

Additional Information

PROFIT X PRICE PSTV

Financial Results PSTV

PSTV cash flow

Asset, Revenue and Profit Growth - PSTV

PSTV balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions